-The Hindustan Times It now seems increasingly unlikely that Parliament will consider the National Food Security Bill during this budget session. In a land which for centuries suffered devastating famines, where chronic hunger continues to stalk more than 200 million people, and which is home to every third malnourished child on the planet, this would be one more sad betrayal of the country's indigent millions, a reminder of how little they...

-The Hindu Business Line     Technology has improved the poor's access to healthcare. India grapples with the issue of a major divide between the well-to-do and the lower end of the population strata. The challenge of uplifting the ‘below the poverty line' section of the population remains a challenging task. One of the areas which ranks high on this priority list is access to healthcare facilities. As is well known, events related to emergency...

KEY TRENDS   • According to National Sample Survey report no. 583: Persons with Disabilities in India, the percentage of persons with disability who received aid/help from Government was 21.8 percent, 1.8 percent received aid/help from organisation other than Government and another 76.4 percent did not receive aid/ help *8   • As per National Family Health Survey-4 (NFHS-4), the Under-five Mortality Rate (U5MR) was 57.2 per 1,000 live births (for the non-STs it was 38.5)...

The recent Supreme Court judgment dismissing pharma giant Novartis’ claim for patent protections in India for its award-winning and prohibitively priced anti-leukemia drug Glivec has renewed the focus on accessibly-priced drugs – in particular the failure of the Indian public healthcare system and health policy to ensure affordable drugs for all. Studies show that as much as 70% of health spending in India comes from out-of-pocket payments, with 50-80% of...

-The Hindu Well before the Supreme Court rejected Novartis' application for patent for Glivec (Gleevec in the U.S.), drawing attention to the dichotomy of generic and patented drugs, activists have been demanding access to expensive drugs used in the treatment of cancer, hepatitis C and serious HIV. Trastuzumab is one such, used in the treatment of HER2+ type of breast cancer, which affects about one in four patients with the disease. Rough...